The estimated Net Worth of Jeff Kent is at least $16.5 Миллион dollars as of 11 May 2021. Jeffrey Kent owns over 12,592 units of Horizon Therapeutics Plc stock worth over $9,721,052 and over the last 6 years he sold HZNP stock worth over $6,731,213. In addition, he makes $0 as Senior Vice President и Head of Medical Affairs and Outcomes Research at Horizon Therapeutics Plc.
Jeffrey has made over 9 trades of the Horizon Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 12,592 units of HZNP stock worth $278,787 on 11 May 2021.
The largest trade he's ever made was selling 57,215 units of Horizon Therapeutics Plc stock on 1 June 2020 worth over $2,857,317. On average, Jeffrey trades about 13,789 units every 47 days since 2019. As of 11 May 2021 he still owns at least 83,586 units of Horizon Therapeutics Plc stock.
You can see the complete history of Jeffrey Kent stock trades at the bottom of the page.
Dr. Jeffrey D. Kent M.D. serves as Senior Vice President, Head of Medical Affairs and Outcomes Research of the Company. Before that Dr. Kent was executive director, medical affairs at Astellas Pharmaceuticals, a public Japanese biopharma company, from 2011 to 2012. Prior to Astellas, he spent more than eight years as global project head for medical affairs in immunology at Abbott Laboratories, then a public health care and pharmaceutical company. Dr. Kent also worked at G.D. Searle & Company (now Pfizer) from 1999 to 2003, and served in various capacities in research and development, including global director for valdecoxib (Bextra) development. A Fellow of the American College of Physicians (FACP) and a Fellow of the American College of Gastroenterology (FACG), Dr. Kent received his M.D. from the Jefferson Medical College in Philadelphia, Pennsylvania.
Jeffrey Kent is 58, he's been the Senior Vice President и Head of Medical Affairs and Outcomes Research of Horizon Therapeutics Plc since 2012. There are 7 older and 17 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
Jeff's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN, L2, 4.
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... и Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include: